EW's Quality Score rose 1 point on Tue, Nov 3, to 15.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 12% in a year while the S&P 500 rose 11%.
| The company | Sales growth sped up 4 quarters in a row |
| Latest filing | 10-Q, Aug 4 |
ReportReports tomorrow, after the close. Every 3 months, a company tells everyone how much it sold and earned. It rose after 2 and fell after 2 of its last 4 reports, +1.5% on average. Past reports ›
After its last 4 reports it closed +1.5% on average, higher 2 of 4 times.
Excellentfor quality, not price, 8 of 14 chart checks firingWhat the Quality Score means
EW is #7 of 85 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 7 |
Sales over four quarters against a year before: EW +15%, STE +8.4%, ZBH +8.6%.
Reports Wed Nov 4, after the close (tomorrow). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
EW's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| TMTT sales | $760M to $780M |
“In 2026, Edwards continues to expect full-year operating profit margin to be at the high end of the company's original 28% to 29% guidance range, resulting in approximately 150 basis points of constant currency operating margin expansion for the full year.”
From its results filing (SEC filing · Jul 23)
Sales grew 6.7% a year over 5 years, fiscal 2020 to 2025.
Its share count fell 1.5% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Jul 23, 2026 | +5.0% | -1.4% | +3.7% |
| Apr 23, 2026 | +3.5% | +5.6% | +4.7% |
| Feb 10, 2026 | +2.0% | +3.0% | +2.5% |
Sales grew in six of the last seven years, to $6.1B in 2025. It made a profit in each of the five years.
6 insiders sold $8.1M across 14 filings in the last 6 months. No open-market buys on record. The newest:
11 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: EW is 0.2% of JEPI, under 0.1% of SPYI, and under 0.1% of VOO, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
“The medical technology industry is highly competitive.”
EW scores 15 today, which Breakaway calls Excellent. It is #7 of 85 in Medical Devices by Quality Score, with 8 of 14 chart checks firing. Up 12% in a year while the S&P 500 rose 11%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
EW scores 15 today, which Breakaway calls Excellent (15 to 19). That is #7 of 85 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind EW's 15.
6 insiders sold $8.1M across 14 filings in the last 6 months. No open-market buys on record. The newest is Andrew M. Dahl, SVP, Corporate Controller, who sold $50K on Aug 31. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.